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Abstract: Unprotected tertiary sulfonimidamides have been
prepared in good to excellent yields in a one-pot transfor-
mation from tertiary sulfinamides through NH transfer. The
reaction is mediated by commercially available (diacetoxyio-
do)benzene and ammonium carbamate in methanol under
convenient conditions. A wide range of functional groups
are tolerated and initial results indicate that the NH transfer
is stereospecific. A small molecule X-ray analysis of NH sulfo-
nimidamide 2 a and its behavior in selected in vitro assays in
comparison to the matched sulfonamide are also reported.
This new reaction provides a safe, short and efficient ap-
proach to sulfonimidamides, which have been the subject of
recent, growing interest in the life sciences.
Introduction
The sulfonamide group 1 (Figure 1) has long been a very im-
portant pharmacophore in drug discovery, being widely used
in anticancer, anti-inflammatory and antiviral agents.[1] In con-
trast, sulfonimidamides 2, the mono-aza analogues of sulfona-
mides, have been rather neglected in the life sciences so far,
despite offering very interesting properties such as high stabili-
ty, favorable physicochemical properties, multiple hydrogen-
bond acceptor/donor functionalities and structural diversity, as
highlighted recently by Arvidsson and co-workers.[2] Arguably,
the use of sulfonimidamides in the life sciences has been ham-
pered by the lack of their commercial availability and the limit-
ed methods available for their synthesis.[3] The “state of the
art“ concerning sulfonimidamides in drug discovery resembles
that of sulfoximines 4,[4] the mono-aza analogues of sulfones 3
(Figure 1), about 15 years ago.
After its late discovery in 1949, the sulfoximine group gar-
nered only a very moderate interest in medicinal chemistry for
many decades. In recent years, however, interest in sulfoximine
chemistry has increased substantially, as evidenced by the de-
velopment of new and safe methods for the preparation of
sulfoximines and the clinical evaluation of at least four novel
sulfoximines, the kinase inhibitors roniciclib (BAY 1000394),[5]
atuveciclib (BAY 1143572),[6] AZD 6738[7] and BAY 1251152.[8] To
the best of our knowledge, a sulfonimidamide candidate has
yet to be evaluated in clinical trials; however, there are a few
recent examples of sulfonimidamides in medicinal chemistry[2]
including an analogue of the clinical anticancer agent tasisu-
lam, with comparable antiproliferative activity against two mel-
anoma cell lines in vitro,[9] and saccharin aza bioisosteres,
which are interesting, new scaffolds for drug design[10]
(Figure 2).
Sulfonimidamides 2 were first synthesized in 1962 by Lev-
chenko and co-workers.[11] Since then, only a few synthetic ap-
proaches for the preparation of sulfonimidamides have been
Figure 1. General structures of sulfonamides 1 (18 R2, R3 = H; 28 R2 = H,
R3¼6 H; 38 R2¼6 H, R3¼6 H), sulfonimidamides 2 (18 R2, R3 = H; 28 R2 = H, R3¼6 H;
38 R2¼6 H, R3¼6 H), sulfones 3 and sulfoximines 4.
Figure 2. Sulfonimidamide-based structure of the analogue of tasisulam and
general structures of novel saccharin aza-bioisosteres.
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reported, usually involving the nucleophilic substitution of a
sulfonimidoyl chloride 7 by an amine (Scheme 1).[12] The re-
quired key chloride intermediates 7 have been prepared
through different strategies that generally hinge on the oxida-
tive imidation of sulfinyl chlorides 5,[11, 13] oxidative chlorination
of sulfinamides 6[14] or deoxychlorination of secondary sulfona-
mides 1.[3, 15] However, most of these protocols require the use
of a protecting group, and deprotection to the corresponding
unprotected NH sulfonimidamides can be challenging. Further-
more, many protocols have a rather limited substrate scope
and/or rely on reagents with an associated safety risk, an ex-
ample being tert-butyl hypochlorite, which is commonly used
for oxidative chlorination despite its explosive nature.[16]
A new synthetic strategy for unprotected tertiary sulfonimi-
damides 2, based on a copper-catalyzed reaction of sulfoxi-
mines 4 a with secondary amines, was disclosed by Bolm and
co-workers in 2016 (Scheme 2).[17] However, this method re-
quires prior synthesis of the corresponding sulfoximine 4 a,
which in our experience can be challenging, depending on the
nature of R1.[18]
During the course of our long-standing interest in sulfoxi-
mines in medicinal chemistry,[19] we have witnessed significant
improvements over the last 15 years towards safe and efficient
synthetic methods for the preparation of sulfoximines. Our at-
tention was captured by a recent report from Luisi, Bull and
co-workers outlining the use of a mixture of ammonium carba-
mate and (diacetoxyiodo)benzene [PhI(OAc)2] for the direct
conversion of sulfoxides 8 into NH sulfoximines 4 at room tem-
perature (Scheme 3).[20] Furthermore, this facile and new NH-
transfer method was applicable to a wide substrate scope and
tolerated a large number of heterocycles and other functionali-
ties.[21] Attracted by the use of commercial reagents and the
robust results of this new one-pot method, we were intrigued
as to whether these safe reaction conditions could also be
useful for the facile synthesis of sulfonimidamides 2 by NH
transfer to sulfinamides 6.
Results and Discussion
Initially, the reported reaction conditions[20] for the imination of
sulfoxides 8 were applied to a commercially available tertiary
sulfinamide. Thus, 1-(phenylsulfinyl)piperidine (6 a ; 100 mg,
0.48 mmol) was treated with ammonium carbamate (4 equiv)
in the presence of PhI(OAc)2 (3 equiv) in methanol at room
temperature for 1 hour (Scheme 4). To our delight, the unpro-
tected tertiary sulfonimidamide 2 a was isolated in 94 % yield
after column chromatography. A scaled-up reaction of sulfina-
mide 6 a (4.0 g, 19.1 mmol) also resulted in a clean conversion
and very good yield (88 %). The structure of sulfonimidamide
2 a was confirmed by X-ray analysis (Figure 3).
Given the clean reaction and high yield, we then elected to
explore the substrate scope of this new process. Our initial
focus was on variation of the NR2R3 group of the sulfinamide 6
and thus, tertiary sulfinamides 6 a–k were subjected to the
standard reaction conditions (Table 1). Gratifyingly, the reac-
tions were generally very clean, resulting in the desired unpro-
tected tertiary sulfonimidamides 2 a–k in good to excellent iso-
lated yields. Only the reaction of sulfinamide 6 d (NR2R3=NiPr2)
Scheme 1. Common strategy for the synthesis of sulfonimidamides 2
through the reaction of amines with sulfonimidoyl chlorides 7, which can be
prepared by a) oxidative imidation of sulfinyl chlorides 5, b) oxidative chlori-
nation of sulfinamides 6 or c) deoxychlorination of secondary sulfonamides
1.
Scheme 4. Synthesis of tertiary NH sulfonimidamide 2 a by NH transfer to
tertiary sulfinamide 6 a.
Scheme 2. Redox-neutral S@C to S@N bond-exchange reaction allowing the
conversion of sulfoximines 4 a into unprotected tertiary sulfonimidamides 2 ;
TC = thiophene-2-carboxylate.
Scheme 3. Synthesis of NH sulfoximines 4 by NH transfer to sulfoxides 8
using ammonium carbamate mediated by the hypervalent iodine reagent
PhI(OAc)2, as described by Bull and Luisi,
[20] and proposed synthesis of terti-
ary NH sulfonimidamides 2 (R2¼6 H, R3¼6 H) from tertiary sulfinamides
6 (R2¼6 H, R3¼6 H) by applying similar reaction conditions.
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resulted in low conversion, presumably due to steric hindrance
of the bulky N,N-diisopropylamino group, with the tertiary sul-
fonimidamide 2 d isolated in 17 % yield along with recovered
starting material. Notably, the reaction of 1,4-bis(phenylsulfi-
nyl)piperazine (6 k) resulted in a double NH transfer to give the
desired product 2 k.
We found, however, that the reaction is limited to the use of
tertiary sulfinamides 6. Subjecting the commercial, primary sul-
finamide 6 l to the standard conditions did not result in forma-
tion of the corresponding sulfonimidamide 2 l ; rather, sulfoni-
midate 9 l was isolated in 58 % yield along with sulfonamide 1 l
(15 % yield, Scheme 5). Reaction of the secondary ethyl sulfina-
mide 6 m resulted in a mixture of products from which sulfoni-
midate 9 m was isolated as the main product. These results are
in line with previous reports of the preparation of sulfonimi-
dates from primary and secondary sulfinamides 6 and hyperva-
lent iodine reagents in the presence of suitable alcohols.[22] The
formation of sulfonamides 1 arising from the standard oxida-
tion of sulfinamides 6 is a side reaction under these condi-
tions.
Next, the scope of the R1 group was explored, with tertiary
sulfinamides 6 n–y being additionally subjected to the stan-
dard reaction conditions (Table 2). Again, the reactions were
very clean, giving the desired unprotected tertiary sulfonimida-
mides 2 n–y in good to excellent isolated yields. Furthermore,
a broad variety of substitution patterns and functional groups
common in medicinal chemistry were tolerated. Similar to the
reaction of the sterically demanding N,N-diisopropylbenzene-
sulfinamide (6 d, Table 1), only the ortho-chloro derivative 6 t
(R1 = 2-ClC6H4) resulted in an incomplete but nevertheless
clean reaction, providing the tertiary sulfonimidamide 2 t in
29 % yield under the standard conditions. However, when the
reaction was repeated using an additional portion of PhI(OAc)2
and ammonium carbamate, there was improved conversion
which resulted in a 48 % isolated yield of 2 t, along with un-
Table 1. Exploration of the substrate scope of the NH transfer reaction:
Variation of the NR2R3 group in tertiary sulfinamides 6 a–k.
Sulfonimidamide NR2R3 Yield
[%][a]
2 a 1-piperidinyl 94
2 b NMe2 72
2 c NEt2 77
2 d NiPr2 17
2 e 1-azetidinyl 71
2 f 1-pyrrolidinyl 77





[a] Isolated yield. [b] Starting material 6 k = 1,4-bis(phenylsulfinyl)pipera-
zine.
Scheme 5. Behavior of primary (6 l) and secondary (6 m) sulfinamides under
the NH transfer reaction conditions.
Table 2. Exploration of the substrate scope of the NH transfer reaction:
Variation of the R1 group in tertiary sulfinamides 6 n–y.
Sulfonimidamide R1 Yield
[%][a]
2 a Ph 94
2 n 4-MeOC6H4 87
2 o 4-FC6H4 89
2 p 4-O2NC6H4 62
2 q 3-F3CC6H4 81
2 r 4-MeC6H4 95
2 r* 4-MeC6H4 88 (48 % ee
[b])
2 s 3-ClC6H4 85
2 t 2-ClC6H4 29 (48)
[c]
2 u 2-pyridyl 85
2 v 3-pyridyl 53
2 w cyclohexyl 88
2 x iPr 70
2 y tBu 83
[a] Isolated yield. [b] ee determined by chiral-phase HPLC analysis; 2 r* ob-
tained from starting material 6 r* with 51 % ee. [c] Additional ammonium
carbamate and PhI(OAc)2 were used.
Figure 3. ORTEP plot (50 % thermal ellipsoids) of the crystal structure of sul-
fonimidamide 2 a.
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reacted starting material. To our delight, sulfinamides with pyr-
idyl or alkyl substituents also reacted successfully to give the
corresponding sulfonimidamides 2 u–y in very good yields, il-
lustrating the broad substrate scope of this new, mild reaction.
As an initial insight into the stereospecificity of this process,
the optically enriched sulfinamide 6 r*, which had been pre-
pared with 51 % ee using the commercial Andersen reagent,[23]
was subjected to the standard reaction conditions. The NH
transfer proceeded stereospecifically to provide product 2 r*
with 48 % ee.
In a preliminary assessment of the medicinal chemistry prop-
erties of sulfonimidamides, the behavior of the fragment-like
sulfonimidamide 2 a compared to the matched sulfonamide
analogue 1 a in selected in vitro assays was undertaken
(Table 3). Considering that our major concern was a possible
inherent instability of the sulfonimidamide group, the hydrolyt-
ic stability of the two compounds at five different pH values
was investigated, along with the metabolic stability in liver mi-
crosomes (human, rat and mouse) and also rat hepatocytes in
vitro. Furthermore, the Caco2 permeability and logD values
were determined. In line with our expectations, sulfonamide
1 a displayed a high hydrolytic stability after 24 hours with stir-
ring in media with pH values ranging from 2.0–7.4 (Table 3).
Moderate hydrolytic stability was evident at pH 8.0, with 67 %
recovered test compound. However, sulfonimidamide 2 a also
has a very high hydrolytic stability, with 100 % recovered test
compound after 24 hours with stirring at all tested pH values.
In vitro pharmacokinetic studies with sulfonamide 1 a revealed
a moderate metabolic stability in human liver microsomes, re-
sulting in a moderate predicted blood clearance (CLb) of
0.41 L h@1 kg@1; however, a low metabolic stability and high pre-
dicted blood clearance of sulfonamide 1 a was evident both in
rat and mouse liver microsomes [CLb = 3.8 L h
@1 kg@1 (rat),
4.0 L h@1 kg@1 (mouse)] . A high blood clearance (4.0 L h@1 kg@1)
was also predicted from in vitro studies with rat hepatocytes.
The main sites of metabolism were not determined in these
studies. In comparison, the matched sulfonimidamide 2 a re-
vealed a trend for higher metabolic stabilities in vitro: studies
with human and mouse liver microsomes resulted in low pre-
dicted blood clearances of 0.04 and 1.1 L h@1 kg@1, respectively.
Sulfonimidamide 2 a exhibited a low metabolic stability in rat
preparations, with correspondingly high predicted CLb values
[3.0 L h@1 kg@1 (rat liver microsomes), 3.6 L h@1 kg@1 (rat hepato-
cytes)] ; however, these data also revealed a trend in rats for a
higher metabolic stability of sulfonimidamide 2 a relative to
sulfonamide 1 a. In the Caco2 screening assay, sulfonamide 1 a
and the matched sulfonimidamide 2 a both had high permea-
bility coefficients (Papp A–B) of 393 and 378 nm s
@1, respectively,
and no evidence of efflux. However, the switch from the sulfo-
namide to the sulfonimidamide results in a remarkable de-
crease in lipophilicity, with a logD value of 2.6 (1 a) compared
to 1.9 (2 a).
Conclusion
We have utilized electrophilic NH transfer to achieve the first
direct synthesis of tertiary NH sulfonimidamides 2 from tertiary
sulfinamides 6. The developed protocol relies on the readily
available nitrogen source ammonium carbamate and the oxi-
dant PhI(OAc)2, and is compatible with a broad substrate
scope, providing the corresponding sulfonimidamides 2 in
good to excellent yields. Initial results indicate that this reac-
tion process is stereospecific; additional investigations are cur-
rently underway. In vitro studies of the properties relevant to
medicinal chemistry for compound 2 a have not revealed any
intrinsic flaw of the sulfonimidamide group with respect to its
application as a new and versatile pharmacophore in the life
sciences.
Experimental Section
General synthetic procedure for sulfonimidamides 2
To the sulfinamide (0.48 mmol, 1.00 equiv) were added (diacetox-
yiodo)benzene (1.43 mmol, 3.00 equiv), ammonium carbamate
(1.91 mmol, 4.00 equiv) and finally MeOH (0.96 mL, 0.5 m). The mix-
ture was stirred in an open flask at RT for 0.5–2 h. When all the
starting material had been consumed (as monitored by TLC and
UPLC-MS), saturated aqueous NaHCO3 solution and EtOAc were
added, and the mixture was stirred for 5 min. The organic layer
was separated and the aqueous layer was extracted with EtOAc
(3 V). The organic phases were combined, washed with brine (3 V)
and dried over water-repellent filter paper. The volatiles were re-
moved under reduced pressure and the crude product was puri-
fied by flash column chromatography.
1-(S-Phenylsulfonimidoyl)piperidine (2 a)
Prepared according to the general procedure, from commercial 1-
(phenylsulfinyl)piperidine (Sigma–Aldrich) ; crude purified by flash






































3.6 378 0.59 1.9
[a] Hydrolytic stability measured as recovery of test compound after 24
hours with stirring at pH 2.0 (citrate buffer), pH 4.5 (citrate buffer), pH 6.5
(phosphate-buffered saline), pH 7.4 (phosphate-buffered saline), and
pH 8.0 (sodium borate buffer).[24] [b] Predicted hepatic metabolic clear-
ance based on a high-throughput metabolic stability assay using
i) pooled human liver microsomes (hLMs), ii) pooled rat liver microsomes
(rLMs), iii) pooled mouse liver microsomes (mLMs), and iv) freshly harvest-
ed rat hepatocytes (rHep).[25] [c] Papp A–B (apical to basolateral) and efflux
ratio (ER) data were generated in a bidirectionally performed Caco2 per-
meability assay in a 24-well format; ER was calculated as Papp B–A/Papp A–
B.[25] [d] Determined by reversed-phase HPLC.[26]
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column chromatography (KP-Sil, 0–40 % EtOAc in hexane) to give
2 a as a yellow-orange solid (105 mg, 94 %): m.p. 99–100 8C;
1H NMR (600 MHz, [D6]DMSO): d= 7.79–7.74 (m, 2 H), 7.66–7.61 (m,
1 H), 7.60–7.55 (m, 2 H), 4.29 (s, 1 H), 2.91–2.74 (m, 4 H), 1.56–1.44
(m, 4 H), 1.30 ppm (q, J = 5.82 Hz, 2 H); 13C NMR (101 MHz,
[D6]DMSO): d= 136.6, 132.0, 128.7, 127.7, 47.4, 25.2, 23.2 ppm; IR
(KBr): ñ= 3234, 2989, 2933, 2837, 1445, 1256, 907, 721, 687,
575 cm@1; HRMS (ESI-TOF) m/z [M+H]+ calcd for C11H17N2OS:
225.1062, found: 225.1066.
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